GH Research PLC (NASDAQ:GHRS - Get Free Report) rose 2.1% during trading on Wednesday . The stock traded as high as $8.34 and last traded at $8.20. Approximately 8,096 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 79,166 shares. The stock had previously closed at $8.03.
Wall Street Analyst Weigh In
GHRS has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.
Check Out Our Latest Stock Analysis on GH Research
GH Research Stock Performance
The stock has a market capitalization of $453.70 million, a PE ratio of -12.61 and a beta of 0.74. The company's fifty day simple moving average is $7.89 and its two-hundred day simple moving average is $10.48.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Sell-side analysts forecast that GH Research PLC will post -0.85 EPS for the current fiscal year.
Hedge Funds Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 80.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,310,563 shares of the company's stock after buying an additional 1,471,946 shares during the quarter. GH Research accounts for 9.1% of Lynx1 Capital Management LP's portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
